COMPARISION OF EFFICACYAND SAFETY OF ORAL LABETALOL AND NIFEDIPINE IN PREECLAMPSIA: A PROSPECTIVE OBSERVATIONAL STUDY

  • Chava. Jhansi Government General Hospital
  • Mandali. Yogya Sree Harshini Professor and Head of the Department, Department of Obstetrics and Gynecology, Government General Hospital, Guntur
  • Kanneganti. Sandeep Government General Hospital
  • P. Chandrasekhara Rao Government General Hospital
  • Ch. Chaitanya Lakshmi Government General Hospital

Abstract

Objective: To compare the efficacy and safety of oral Labetalol and Nifedipine in preeclampsia patients and to aid professionals in making appropriate therapeutic decisions in the management of preeclampsia.

Methods: A Prospective observational study with the total of 152 pregnant women with preeclampsia is conducted in a Tertiary Care Hospital in India. Pregnant women with preeclampsia prescribed with either oral labetalol or oral nifedipine were selected. Main outcome measures include monitoring of adverse effects of labetalol and nifedipine and efficacy of both drugs. Blood pressures were measured every 4 hrs using sphygmomanometer and average of three consecutive readings is recorded. The two groups were followed until delivery and are interviewed for any adverse reactions.

Results: The duration of days required for labetalol to normalize the high blood pressure is 5 days (5±2.63 d), and that of nifedipine is 7.5 days (7.5±3.83 d) with P value of 0.0015. Common adverse Drug reactions (ADR’s) of the both drugs are pedal edema (50%, 47.36%), headache (44.7%, 26.31%), and orthostatic hypotension (9%, 7%) etc are compared.

Conclusion: Oral Labetalol is more efficacious than Oral Nifedipine, with an exception of more adverse effects and high cost.

 

Keywords: Preeclampsia, Safety, Efficacy, Labetalol, Nifedipine

Downloads

Download data is not yet available.

References

1. Introduction to Preeclampsia. WHO recommendations for Prevention and Treatment of Pre-eclampsia and eclampsia. WHO Handbook for guideline development. Geneva, World Health Organization; 2010.
2. Preeclampsia Introduction. Hypertensive disorders of pregnancy. Queensland Maternity and Neonatal Clinical Guideline; 2010. p. 7.
3. Pre-eclampsia. Alabama perinatal excellence collaborative guidelines. Protocol; 2014.
4. Classification of Hypertensive Disorders. ACOG 2013;2:13-5.
5. Preeclampsia: Hypertension in pregnancy report of the american college of obstetricians and gynecologists' task force on hypertension in pregnancy. ACOG 2013;122:1122-31.
6. The impact of preeclampsia. Preeclampsia and Maternal Mortality: A Global Burden; 2013.
7. Kayode O Osungbade, Olusimbo K Ige. Public Health Perspectives of Preeclampsia in Developing Countries: Implication for Health System Strengthening. J Pregnancy 2011. doi.org/10.1155/2011/481095. [Article in Perss]
8. Management of Preeclampsia. Hypertension in Pregnancy Pathway. National Instituite for Health and Clinical Excellence (NICE); 2014.
9. Liu QQ, Yu YH, Gong SP, Huang LP. Clinical efficacy and perinatal outcome of nifedipine for severe preeclampsia: meta-analysis. Zhonghua Fuchanke Zazhi 2012;47:592-7.
10. Nita K Patel, Mansi Gadhavi, Dhaval Gorasia, Manish R Pandya. Comparative evaluation of antihypertensive drugs in the management of pregnancy-induced hypertension. Int J Basic Clin Pharmacol 2012;1:174-7.
11. Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2006;19:CD001449.
12. Prevention of Preeclampsia. Hypertension in pregnancy report of the american college of obstetricians and gynecologists' task force on hypertension in pregnancy. ACOG 2013;122:27-9.
13. McDonald AJ, Yealy DM, Jacobson S. Oral labetalol versus oral nifedipine in hypertensive urgencies in the ED. Am J Emerg Med 1993;11:460-3.
Statistics
512 Views | 1742 Downloads
How to Cite
Jhansi, C., M. Y. S. Harshini, K. Sandeep, P. C. Rao, and C. C. Lakshmi. “COMPARISION OF EFFICACYAND SAFETY OF ORAL LABETALOL AND NIFEDIPINE IN PREECLAMPSIA: A PROSPECTIVE OBSERVATIONAL STUDY”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 7, no. 9, July 2015, pp. 277-80, https://innovareacademics.in/journals/index.php/ijpps/article/view/6767.
Section
Original Article(s)